OTC Watch

All stocks / HEPA

Hepion Pharmaceuticals, Inc. HEPA

Hepion Pharmaceuticals (HEPA): shares outstanding up 976% in a year, convertible notes mentioned in an 8-K in September 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

DilutionEstimated floatCostly financing OTCQBNew Jersey, USA
Live quote on OTC Markets

Market listing

Full name
HEPION PHARMACEUTICALS INC
Market tier
OTCQB
Trading status
Active
Last trade
Nov 16
Website
hepionpharma.com
Source: Stockwatch, 2026-11-17

News headlines

Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest
2026-10-26 08:01 · News Release
Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication
2026-10-19 08:01 · News Release
Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update
2026-10-14 08:06 · News Release
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
2026-03-03 07:35 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Net loss
($8,277,850)
What it means

It spends more than it earns

Under strain

The company lost $8.3 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$1,828,062
Net cash used in operating activities
($3,271,520)
What it means

The cash could run out soon

Under strain

It had $1.8 million in the bank and used about $272,627 a month. At that pace the money lasts about 7 months unless it borrows or sells more shares.

The report says
Total assets
$3,069,952
Total liabilities
$402,405
What it means

It owns more than it owes

Steady

Everything the company owns adds up to $3.1 million. Its debts and unpaid bills add up to $402,405. That is about $0.13 owed for every $1 owned.

What this adds up to

2 of 3 checks show strain. It spends more than it earns. The cash could run out soon. These are facts from the company's own reports, not a recommendation.

Signals

Dilution2026-11-08

Shares outstanding rose from 11,620,317 (2025-11-12) to 125,074,297 (2026-11-08), up 976%.

Rule: Shares outstanding up 20% or more in 12 months. Source record

Estimated float2026-11-08

Estimated float about 98,374,297 shares as of 2026-11-08: 125,074,297 outstanding minus 26,700,000 held by 6 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Costly financing2026-09-08

8-K filed 2026-09-08 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Shares outstanding

Source: SEC filings
2025-12-31
11.6M
2026-03-11
11.6M
2026-03-31
11.6M
2026-05-14
29.1M
2026-06-30
29.1M
2026-08-10
90.2M
2026-09-30
100.1M
2026-11-08
125.1M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-16 10-Q10-Q
2026-10-27 44
2026-10-27 44
2026-10-27 44
2026-10-27 44
2026-10-27 44
2026-10-27 44
2026-10-27 44
2026-10-27 44
2026-10-26 SCHEDULE 13D
2026-10-21 33
2026-10-21 SCHEDULE 13G/A

Common questions about HEPA

Does HEPA file reports with the SEC?

Yes. Hepion Pharmaceuticals files with the SEC under company number 0001583771. The most recent filing we hold is a 10-Q dated 2026-11-16.

Source record

How many HEPA shares are outstanding?

125,074,297 shares as of 2026-11-08, as reported to the SEC. That is up 976% from 11,620,317 on 2025-11-12.

Source record

Has HEPA filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs Hepion Pharmaceuticals?

Officers named in its insider filings: Sireesh Appajosyula (Chief Executive Officer), Chase LoPriore (VP, Corp. Dev.) and Vincent S LoPriore (Executive Chairman).

Source record

Is Hepion Pharmaceuticals making money?

The company lost $8.3 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record